Michael Forbes, CEO of Adastra, said in his Original press release: “Hurt reduction can be a critically important and mainstream matter, and we are staying on the forefront of drug regulations over the board.”“We will evaluate how the commercialization of the substance fits in with our business design at Adastra in an effort to place ourselve